ReviewGene therapy2009
Progress and prospects: biological properties and technological advances of herpes simplex virus type 1-based amplicon vectors.
Review in Gene therapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Next-generation replication-defective HSV vectors for delivery of large DNA payloads.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
- Non-replicative herpes simplex virus genomic and amplicon vectors for gene therapy - an update.Gene therapy · 2025Review
- Nucleic Acid Therapy for the Skin.The Journal of investigative dermatology · 2025Review
- Cancer vaccines: an update on recent achievements and prospects for cancer therapy.Clinical and experimental medicine · 2024Review
- Highly Efficient Microcell-Mediated Transfer of HACs Containing a Genomic Region of Interest into Mammalian Cells.Current protocols · 2021Article
- Improvement of HSV-1 based amplicon vectors for a safe and long-lasting gene therapy in non-replicating cells.Molecular therapy. Methods & clinical development · 2021Article
- Gene Therapy Tools for Brain Diseases.Frontiers in pharmacology · 2019Review
- A Matter of Genes: The Hurdles of Gene Therapy for Epilepsy.Epilepsy currents · 2019Article
- Programming gene and engineered-cell therapies with synthetic biology.Science (New York, N.Y.) · 2018Review
- Transformation-associated recombination (TAR) cloning for genomics studies and synthetic biology.Chromosoma · 2016Review
- A new generation of human artificial chromosomes for functional genomics and gene therapy.Cellular and molecular life sciences : CMLS · 2013Review
- Gene transfer in inner ear cells: a challenging race.Gene therapy · 2013Review
- Gene therapy for the treatment of chronic peripheral nervous system pain.Neurobiology of disease · 2012Review
- Human artificial chromosome (HAC) vector with a conditional centromere for correction of genetic deficiencies in human cells.Proceedings of the National Academy of Sciences of the United States of America · 2011Article
- Advances in Gene Delivery Systems.Pharmaceutical medicine · 2011Article
- Future viral vectors for the delivery of asymptomatic herpes epitope-based immunotherapeutic vaccines.Future virology · 2010Article
- Herpesvirus vectors in gene therapy.The open virology journal · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The last two years have seen significant advances in our understanding of the cellular innate responses elicited or activated by the entry of amplicon particles, which may, in part, explain the transient nature of transgene expression often observed in cells infected with helper-free amplicon stocks. At the technological level, the most consistent progress has been in strategies to enhance the stability of transgene cassettes, either through integration into host chromosomes or through the conversion of the amplicon genome into a replication-competent extrachromosomal element.
Indexed as
Identifiers
19369969What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.